Clinical Trials Browser

Recruiting × Thrombocythemia, Essential × 90 days × Clear all

NCT06034002 2026-04-17

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT07441694 2026-04-15

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06661915 2026-04-13

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Phase 2 Recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT07008118 2026-04-06

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06351631 2026-04-02

MK-3543-017

Phase 3 Recruiting

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06063486 2026-03-27

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Phase 2 Recruiting

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05936359 2026-03-24

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05198960 2026-03-20

AVAJAK

Phase 3 Recruiting

Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05123365 2026-03-10

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Phase 1/2 Recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04942080 2026-03-06

CALRSUIVI

Phase NA Recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT04645199 2026-02-12

NICHE

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Hemolytic, Autoimmune, Hemophilia B, Hemoglobinuria, Paroxysmal, Hemophilia A, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Hemostatic Disorders, Leukemia, Large Granular Lymphocytic

NCT07362225 2026-01-23

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Disease Progression, Bone Marrow Neoplasms, Hematologic Neoplasms, Rare Diseases, Primary Myelofibrosis